AIM: To observe the efficacy of Bevacizumab intravitreal injection combined with compound trabeculectomy in the treatment of neovascular glaucoma(NVG).

METHODS: The 36 eyes were with bevacizumab intravitreal injection 1wk before surgery, and then were treated with trabeculectomy combined with mitomycin. The visual acuity, intraocular pressure, follicle, anterior chamber, regression of iris neovascularization, the number of anti-glaucoma drugs used and others were observed before injection, 1d after intravitreal injection, 1, 3, 6, and 12mo after surgery, respectively.

RESULTS: Total success was achieved in 26 eyes, partial success in 7 eyes and failure in 3 eyes at 1a after surgery. The IOP of 1mo(18.183±6.993mmHg), 3mo(19.586±6.198mmHg), 6mo(18.722±5.263mmHg)and 12mo(19.089±4.133mmHg)after surgery were significantly lower than those before injection(39.997±5.827mmHg)and 1d after injection(39.647±5.690mmHg; all P<0.05). The IOP of 1mo and 6mo after surgery was significantly lower than that of 3mo after surgery, and the difference was statistically significant(P<0.05). There was no statistically significant difference between the other two time points postoperatively(all P>0.05). The LogMAR visual acuity of 1mo(0.686±0.202), 3mo(0.622±0.157), 6mo(0.631±0.179)and 12mo(0.711±0.177)after surgery were significantly higher than that before injection(0.833±0.207)and 1d after injection(0.806±0.188), and the differences were statistically significant(all P<0.05). The LogMAR visual acuity of 3mo and 6mo after surgery were significantly higher than that of 1mo after surgery(all P<0.05). The LogMAR visual acuity of 12mo after surgery was significantly worse than that of 3mo and 6mo after surgery(all P<0.05). There was a significant difference in the number of anti-glaucoma drugs used before and after treatment with this method(t=11.131, P<0.05).

CONCLUSION: The bevacizumab intravitreal injection combined with compound trabeculectomy is effective in the treatment of NVG.